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Abstract
Objectives To investigate the prognosis associated with stable
angina in a contemporary population as seen in clinical
practice, to identify the key prognostic features, and from this to
construct a simple score to assist risk prediction.
Design Prospective observational cohort study.
Setting Pan-European survey in 156 outpatient cardiology
clinics.
Participants 3031 patients were included on the basis of a new
clinical diagnosis by a cardiologist of stable angina with
follow-up at one year.
Main outcome measure Death or non-fatal myocardial
infarction.
Results The rate of death and non-fatal myocardial infarction
in the first year was 2.3 per 100 patient years; the rate was 3.9
per 100 patient years in the subgroup (n = 994) with
angiographic confirmation of coronary disease. The clinical
and investigative factors most predictive of adverse outcome
were comorbidity, diabetes, shorter duration of symptoms,
increasing severity of symptoms, abnormal ventricular function,
resting electrocardiogaphic changes, or not having any stress
test done. Results of non-invasive stress tests did not
significantly predict outcome in the population who had tests
done. A score was constructed using the parameters predictive
of outcome to estimate the probability of death or myocardial
infarction within one year of presentation with stable angina.
Conclusions A score based on the presence of simple, objective
clinical and investigative variables makes it possible to
discriminate effectively between very low risk and very high risk
patients and to estimate the probability of death or non-fatal
myocardial infarction over one year.
Introduction
Prognostic assessment is a crucial component of clinical
assessment at all levels of care in cardiovascular disease.
Although stable angina is the most prevalent manifestation of
coronary disease, affecting up to 5% of the adult population aged
over 40 in most developed countries,1 2 contemporary informa-
tion on the prognosis of the condition is relatively sparse.
To ensure their reliability, risk prediction models may need to
be modified according to the population to which they are
applied and regularly updated.3 4 The Framingham model, a well
constructed and validated risk prediction algorithm based on
epidemiological data updated with refreshed intake in the 1970s,
has been shown to overestimate risk when applied in contempo-
rary European populations.5 6 These principles apply in similar
measure to prediction of risk in populations with stable
symptoms, where predictive models are less often applied.
The aims of this investigation were to ascertain the prognosis
associated with a clinical diagnosis of stable angina in a contem-
porary setting; to determine the clinical and investigative factors
predictive of death or myocardial infarction; and to construct a
simple, user friendly risk prediction model to assist in prognostic
evaluation of stable angina.
Methods
The Euro heart survey of stable angina was designed as a
prospective observational cohort study of patients presenting to
cardiology services with stable angina. Participating centres were
a mix of academic and non-academic institutions, and hospitals
with and without interventional and cardiac surgical facilities.
The 3031 patients included in the survival analysis were enrolled
from 156 centres in 34 countries. The number of patients
included in each centre ranged from 1 to 106, with a median of
17 patients and interquartile range of 8 to 22. The number of
centres in each country ranged from 1 to 27, with a median of 2
and an interquartile range of 1 to 6. Further details of centres,
data collection, and patient population have previously been
described.7
Patient population and follow-up
Briefly, patients attending cardiology services with a new presen-
tation of stable angina were considered for enrolment, and con-
secutive patients in whom the cardiologist made a clinical
diagnosis of stable angina caused by myocardial ischaemia due
to coronary disease were included in the survey. All patients gave
informed consent. We defined a new presentation as a first ever
presentation to a cardiologist or a new referral or re-referral after
a period of at least one year of not consulting a cardiologist.
Exclusion criteria included unstable angina, admission to hospi-
tal within 24 hours of assessment, myocardial infarction within
one year, previous revascularisation, or a cause of angina other
than coronary disease. Follow-up was done by clinical review or
telephone contact as close as possible to one year from initial
assessment. The occurrence and dates of occurrence of death or
cardiovascular events were recorded, as well as the cause of death
if available. The local investigators adjudicated clinical end points
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according to the definitions in appendix A on bmj.com. Severity
of angina was assessed by using the Canadian Cardiovascular
Society classification. Known cardiovascular risk factors and
comorbid conditions were defined as in appendix A.
Statistical analysis
We used descriptive statistics to estimate the prevalence of risk
factors, baseline clinical characteristics, and treatment at presen-
tation. We used Student’s t test or analysis of variance as appro-
priate to test for significant differences in quantitative measures
and the 2 test to test for significant differences in proportions.
The primary outcome of interest was the occurrence of death or
non-fatal myocardial infarction. In the analysis of the primary
outcome we defined follow-up time from enrolment into the
study to the time of the first event (death or non-fatal myocardial
infarction) or 18 months after recruitment. Follow-up was
censored at 18 months if no event was recorded.
We used appropriate survival analysis techniques to calculate
event rates.8 We assessed differences between groups in the
cumulative probability of the primary end point or of all cardio-
vascular events by using the log rank test. We used Cox’s propor-
tional hazards models to determine the effects of clinical and
investigative variables on the occurrence of death or non-fatal
myocardial infarction in both univariate and multivariate analy-
sis. Starting with clinical variables, we did stepwise regression
(using entry/removal P value = 0.15) to determine the factors
predictive of death or infarction during follow-up. Stepwise
selection may lead to unstable results if the variables considered
for inclusion in the final model are highly correlated. To avoid
this, we used both forward and backward methods, as these (if
leading to inconsistent selections) would indicate the presence of
colinearity and therefore potentially inappropriate multivariate
models. We developed models separately for clinical and investi-
gative parameters and then for a combination of clinical and
investigative parameters. We refitted the final model for all
patients without missing values for the variables selected. We
used likelihood ratio tests to test the predictors’ significance and
to assess presence of departure from a linear effect for continu-
ous variables.
To develop a scoring system for predicting the probability of
death or infarction during the first year after presentation that
was based only on objective information generally available to
clinicians and not on whether a test was done, we developed a
further multivariate model without the stress test done/not done
variable, as outlined in appendix B on bmj.com. We assessed the
performance of the model by calculating the Harrell’s C-statistic
(comparable to the area under the receiver operating character-
istics curve).9 We used Stata version 9 statistical software for all
analyses.
Results
From March 2002 to December 2002, 3779 patients with stable
angina were enrolled into the study. Vital status during follow-up
was ascertained in 3259 (86%) patients, and data were suitable
for survival analysis for the primary outcome of interest, which
included non-fatal myocardial infarction, in 3031. The median
duration of follow-up was 13 (interquartile range 12-15) months.
No substantial differences existed between the patients with and
without follow-up information in terms of clinical characteristics
(table 1) or regional distribution. Thus the survival analysis
results, which are based on the 3031 patients with follow-up data,
can be treated as indicative of the overall survival experience.
The population was relatively young—mean age 61 years—and
58% were male. Most patients had mild to moderate symptoms
of angina for six months or less before presentation to a
cardiologist, although only 48 (1.7%) patients had symptoms for
less than one month before cardiology assessment.
Confirmation of coronary disease
Coronary angiography was done at least once during follow-up
in 1253 (41%) patients. At the end of the follow-up period,
approximately one third (n = 994) of patients had had coronary
disease confirmed angiographically and a further third
(n = 1023) had negative investigations. One sixth of patients had
no definitive diagnostic test to confirm the presence or absence
of coronary disease (table 2).
Table 1 Baseline clinical characteristics of patients with and without
completed clinical follow-up. Values are numbers (percentages) unless
stated otherwise
Variable
Follow-up
incomplete (n=748)
Follow-up
complete (n=3031) P value*
Mean (SD) age (years) 61 (11) (n=742) 61 (11) (n=2989) 0.85
Female sex 311/748 (42) 1271/3031 (42) 0.83
Symptom severity (CCS class): n=706 n=2766
0.15
Class I 251(36) 1096 (40)
Class II 360 (51) 1331 (48)
Class III 95 (13) 339(12)
Duration of angina symptoms: n=706 n=2814
<1 month 4 (<1) 48 (2)
0.18
1-5 months 365 (52) 1494 (53)
6-11 months 155 (22) 585 (21)
≥12 months 182 (26) 687 (24)
Previous MI (>1 year before) 13/445 (3) 117/2456 (5) 0.08
Peripheral vascular disease 51/748 (7) 216/3031 (7) 0.76
Previous TIA or CVA 46/748 (6) 151/3031 (5) 0.20
Respiratory disease 66/748 (8) 247/3031 (8) 0.54
Renal failure 7/748 (1) 47/3031 (2) 0.20
Chronic inflammatory conditions 16/748 (3) 90/3031 (3) 0.22
Peptic ulcer disease 47/748 (6) 197/3031 (6) 0.79
Malignancy 14/748 (2) 47/3031 (2) 0.53
Diabetes 122/713 (17) 530/2953 (18) 0.59
Hypertension 458/727 (63) 1809/2949 (61) 0.39
Smoking status: n=725 n=2828
0.71Ex-smoker 220 (30) 844 (30)
Current smoker 173 (24) 646 (23)
Hyperlipidaemia 391/629 (62) 1452/2545 (57) 0.02
Signs of heart failure 75/747 (10) 221/3022 (7) 0.01
Mean (SD) systolic BP (mm Hg) 144 (22) (n=748) 145 (21) (n=3001) 0.43
Mean (SD) body mass index 28 (4) (n=668) 28 (4) (n=2738) 0.79
Drugs at baseline: n=748 n=3031
Aspirin 374 (50) 1602 (47) 0.16
Statin 184 (25) 1429 (21) 0.04
 blocker 262 (35) 1142 (38) 0.18
BP=blood pressure; CCS=Canadian Cardiology Society; CVA=cerebrovascular event;
MI=myocardial infarction; TIA=transient ischaemic attack.
*For differences in proportions or means between patients with and without complete
follow-up data.
Table 2 Coronary disease status according to level of diagnostic
investigation completed at end of follow-up (n=3031).
Coronary disease status No (%)
Confirmed coronary artery disease (obstructive coronary disease defined
as at least 50% stenosis of an epicardial vessel confirmed at coronary
angiography)
994 (33)
Positive non-invasive tests (positive non-invasive tests without
angiography)
486 (16)
Incomplete investigation (no functional assessment or angiography, or
inconclusive result from functional assessment)
528 (17)
Negative investigation (negative coronary angiography or, in the absence
of angiography, negative non-invasive tests)
1023 (34)
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Clinical events during follow-up
Table 3 shows the numbers of individual clinical events and the
annual rates of clinical events in the overall study population and
the subgroup with confirmed coronary disease. The incidence of
death or infarction was significantly greater (P < 0.001) in
patients with confirmed coronary disease than in those with
negative investigations or positive non-invasive tests without
angiographic confirmation of disease (fig 1). However, patients
who had no investigation, or inconclusive results on non-invasive
investigation that were not pursued further, had a rate of death
or infarction—4.1/100 patient years (95% confidence interval 2.7
to 6.0)—that was similar to that in the population with confirmed
coronary disease. Non-cardiovascular death did not seem to
contribute a disproportionate number of these deaths, account-
ing for only 7/21 (33%) deaths. This was a similar proportion to
that seen in the group with positive non-invasive tests (1/3, 33%)
and less than the proportion seen in the group with negative
investigations (4/7, 57%), although it was higher than the
proportion seen in the group with confirmed coronary artery
disease (2/19, 11%).
Clinical and investigative factors predictive of adverse
outcome
Table 4 shows the risk of death or myocardial infarction
associated with baseline clinical characteristics and results of
investigations. Previous myocardial infarction, signs of heart fail-
ure, or a past history of diabetes, hypertension, or any comorbid-
ity were significant predictors of adverse outcome, as were
increasing severity of symptoms and shorter duration of
symptoms. Resting electrocardiographic abnormalities (Q wave
or ST/T wave changes) were associated with approximately dou-
ble the risk of death or myocardial infarction, but positive
non-invasive stress test results were not significantly associated
with adverse outcome. As the numbers of patients with stress
imaging techniques were small, we created a new indicator to
summarise the information on all forms of functional
assessment (exercise electrocardiogram, stress echocardiogram,
or perfusion). Not having had any functional assessment was an
indicator of substantially increased risk, as was abnormal left
ventricular function assessed by echocardiography.
Table 3 Major clinical events occurring during follow-up in the overall population and in patients with confirmed coronary disease
End point
Stable angina (n=3031) Stable angina with confirmed CAD (n=994)
No of events
Event rate (95% CI) per 100 patient
years No of events Event rate (95% CI) per 100 patient years
Death* 50 1.5 (1.1 to 1.9) 19 1.8 (1.1 to 2.8)
Non-cardiovascular death 14 (28%) 2 (11%)
Non-fatal myocardial infarction 48 1.4 (1.1 to 1.9) 34 3.2 (2.3 to 4.4)
Death and non-fatal myocardial infarction 93 2.3 (1.9 to 2.8) 50 3.9 (2.9 to 5.1)
Cerebrovascular event 34 1.1 (0.8 to 1.5) 15 1.6 (1.0 to 2.6)
Heart failure 49 1.5 (1.1 to 2.0) 20 2.1 (1.3 to 3.2)
Unstable angina 164 5.2 (4.4 to 6.0) 114 12.1 (10.1 to 14.6)
All cardiovascular events† 328 10.3 (9.3 to 11.5) 207 21.9 (19.1 to 25.2)
CAD=coronary artery disease.
*Of 50 deaths, the cause of death was classified as unknown or missing in six and cardiac or cardiovascular in 29.
†Cardiovascular death, non-fatal myocardial infarction, unstable angina, heart failure, stroke, and emergency revascularisation.
Time since entry (months)
Cu
m
ul
at
iv
e 
pr
ob
ab
ili
ty
0 3 6 9 12 15 18
0
0.04
0.08
0.10
0.02
Confirmed coronary disease
Log rank P<0.001
Negative investigation
Positive non-invasive investigation
Incomplete investigation
Fig 1 Cumulative probability of death or non-fatal myocardial infarction during
follow-up in patients with stable angina, according to diagnostic level of
confirmation of coronary disease
Table 4 Unadjusted hazard ratio of death or myocardial infarction
associated with clinical and investigative parameters in general population
with stable angina (n=3031)
Hazard ratio (95% CI) P value*
Clinical variables
Age (per 1 year increment) 1.03 (1.01 to 1.05) 0.001
Sex (female v male) 1.19 (0.79 to 1.79) 0.40
Diabetes 2.40 (1.55 to 3.70) <0.001
Hypertension 2.12 (1.29 to 3.48) 0.002
Hyperlipidaemia 1.00 (0.63 to 1.58) 0.99
Ever smoked 1.53 (1.00 to 2.36) 0.05
Previous myocardial infarction 3.24 (1.72 to 6.13) 0.002
Comorbidity 2.98 (1.98 to 4.52) <0.001
Symptom severity:
Class II versus class I 2.34 (1.37 to 4.00)
0.0002
Class III versus class I 3.44 (1.80 to 6.55)
Symptom duration >6 months 0.60 (0.39 to 0.94) 0.03
Signs of heart failure 2.67 (1.56 to 4.57) 0.001
Body mass index >30 0.82 (0.49 to 1.37) 0.43
Tertiary education 0.78 (0.40 to 1.52) 0.46
Investigative variables
Left bundle branch block 1.50 (0.66 to 3.43) 0.34
Q wave 2.37 (1.38 to 4.06) 0.002
ST or T wave changes 2.26 (1.50 to 3.41) <0.001
Ischaemic ECG changes† 2.27 (1.50 to 3.43) <0.001
Result of individual stress tests:
Positive exercise ECG‡ (n=2299) 1.44 (0.80 to 2.61) 0.22
Positive stress echocardiogram‡
(n=119)
1.24 (0.24 to 6.40) 0.80
Positive perfusion scan‡ (n=420) 3.55 (0.77 to 16.47) 0.07
Result of any stress test§:
Positive test 1.50 (0.82 to 2.73) <0.0001
No test done 4.42 (2.50 to 7.82)
Echocardiography (before events):
Abnormal left ventricular function¶ 5.21 (3.19 to 8.49) <0.001
ECG=electrocardiogram.
*Likelihood ratio test for heterogeneity among category specific rates (hazards) for variables
categories.
†One or more of ST or T wave changes, Q waves, or left bundle branch block.
‡Versus negative or inconclusive.
§Exercise ECG, stress echocardiogram, or perfusion scan; versus negative test.
¶Moderate or poor left ventricular function detected on echocardiography, provided test was
done before events occurring during follow-up.
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Stepwise regression selected comorbidity, diabetes, recent
onset of symptoms, more severe symptoms, ST or T wave abnor-
malities on the resting electrocardiogram, not having any stress
test done, and abnormal ventricular function as the variables
most predictive of outcome (table 5). Age and sex were not
significant predictors when forced into the model. Although age
had a linear effect that was significant when examined on its own
(table 4), its strong association with most of the other variables
led to its lack of significance in the multivariate model (highly
significant association with all variables except “ST or T wave
change”).
Development of a clinical risk score for patients with stable
angina
As non-performance of a test is not an objective measure of a
patient but can be influenced by many physician related and
non-clinical factors, we used a further stepwise selection process
to consider only the results of non-invasive investigations that
had been done. A positive versus negative or inconclusive
non-invasive stress test result was not selected as a significant
predictor of outcome when combined with information from
echocardiography and resting electrocardiography. Thus in the
model developed to derive the clinical risk score the final predic-
tors of death or myocardial infarction were comorbidity,
diabetes, severity of symptoms, duration of symptoms, resting
electrocardiogram abnormalities, and abnormal ventricular
function. Using each of these parameters a risk score can be cal-
culated according to the weighted scores shown in table 6. This
score can then be used to estimate visually the probability of
death or myocardial infarction from the plot in figure 2 or (using
the closest rounded figure) to read the estimated probability
from table 7. Applying the model developed on 75% of the
population to the remaining 25% of the population gave a
C-statistic for the angina score to predict outcome of 0.74.
Discussion
The Euro heart survey of stable angina population differs from a
general selection of people with angina in the community, many
of whom may not have a diagnosis, and differs from the overall
primary care angina population in that they have been selected
for specialist assessment. However, the population is compara-
Table 5 Clinical and investigative parameters independently predictive of
death or myocardial infarction, determined by using stepwise selection
procedures in general population with stable angina
Hazard ratio (95% CI) P value*
Clinical variables (n=2183)
Comorbidity 2.41 (1.49 to 3.91) <0.001
Signs of heart failure 1.62 (0.85 to 3.07) 0.14
Previous myocardial infarction 2.19 (1.08 to 4.42) 0.03
Diabetes 2.03 (1.25 to 3.31) 0.004
Symptom duration >6 months 0.54 (0.33 to 0.87) 0.01
Symptom severity:
Class II versus class I 1.95 (1.07 to 3.54)
0.005
Class III versus class I 2.65 (1.29 to 5.50)
Investigative variables (n=2963)
Stress testing:
Positive test 1.43 (0.76 to 2.70)
0.0001
No stress test done 3.78 (2.04 to 7.00)
Echocardiography:
Abnormal left ventricular function 2.57 (1.62 to 4.08) <0.0001
Electrocardiography:
ST or T wave changes 1.63 (1.06 to 2.50) 0.03
Combined clinical and investigative variables (n=2528)
Comorbidity 2.25 (1.43 to 3.56) 0.0008
Diabetes 1.95 (1.22 to 3.11) 0.007
Previous myocardial infarction —
Symptoms >6 months 0.48 (0.30 to 0.77) 0.002
Symptom severity:
Class II versus class I 1.76 (1.00 to 3.09)
0.05
Class III versus class I 2.18 (1.10 to 4.33)
ST or T wave changes 1.56 (0.99 to 2.45) 0.05
Stress test:
Positive stress test result 1.29 (0.63 to 2.67)
<0.0001
No stress test done 3.48 (1.71 to 7.07)
Abnormal left ventricular function 2.11 (1.29 to 3.46) 0.004
*Likelihood ratio test for heterogeneity among category specific rates (hazards) for variables
categories.
Table 6 Score sheet to calculate risk score for patients presenting with
stable angina
Risk factor Score contribution Individual’s score
Comorbidity*
No 0
Yes 86
Diabetes
No 0
Yes 57
Angina score
Class I 0
Class II 54
Class III 91
Duration of symptoms
≥6months 0
<6 months 80
Abnormal ventricular function
No 0
Yes 114
ST depression or T wave inversion on resting electrocardiogram
No 0
Yes 34
Total=
*One or more of previous cerebrovascular event; hepatic disease defined as chronic hepatitis
or cirrhosis, or other hepatic disease causing elevation of transaminases more than three
times upper limit of normal; peripheral vascular disease defined as claudication either at rest
or on exertion, amputation for arterial vascular insufficiency, vascular surgery (reconstruction
or bypass) or angioplasty to the extremities, documented aortic aneurysm, or non-invasive
evidence of impaired arterial flow; chronic renal failure defined as chronic dialysis or renal
transplantation or serum creatinine greater than 200 mol/l; chronic respiratory disease
defined as a diagnosis previously made by physician or patient receiving bronchodilators or
FEV1<75%, arterial pO2<60%, or arterial pCO2>50% predicted in previous studies; chronic
inflammatory conditions defined as a diagnosis of rheumatoid arthritis, systemic lupus
erythematosis or other connective tissue diseases, polymyalgia rheumatica, and so on;
malignancy defined as a diagnosis of malignancy within a year or active malignancy.
Individual total score
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Fig 2 Plot to assign estimated probability of death or non-fatal myocardial
infarction within one year of presentation according to combination of clinical and
investigative features in patients with stable angina (corresponding to scoring
system in table 7). MI=myocardial infarction
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tively less highly selected than those in randomised controlled
trials or angiographic registries.
Comparisons with clinical trial populations with stable
angina
The annual incidence of death in the survey was 1.5%, and the
incidence of non-fatal myocardial infarction was 1.4%. In the
subgroup with proved coronary disease these rates were 1.8%
and 3.2%. Estimates of annual mortality from modern clinical
trials of secondary prevention, antianginal treatment, or revascu-
larisation range from 0.9% to 1.7%,10–13 with a higher mortality in
populations with more severe symptoms.10 Reported annual
incidences of non-fatal myocardial infarction range from 1.1% to
1.5%.11 12
Determining prognosis in an individual
The process of assessing prognosis in stable angina serves
several purposes: to facilitate an informed response to the
patient’s own queries and answer specific questions from
employers and insurers, to determine the need for further inves-
tigation or specialist opinion, and to assist in choosing appropri-
ate treatment.
On the whole the features identified in this study as predict-
ing adverse outcome in the population with stable angina are in
keeping with previous observations in registry data.14 15
Importantly, negative investigations, either invasive or non-
invasive, identify a low risk population. Even with the relatively
short follow-up in this survey, the prognostic importance of
comorbidity is substantial, of the same order as the impact of
abnormal ventricular function. This has also recently been
shown in a study from the Duke database.16 A further important
finding is that, in this population with largely uncomplicated sta-
ble angina (few patients had evidence of heart failure or previous
myocardial infarction), the severity of angina, as measured by the
simple and widely used Canadian Cardiovascular Society classi-
fication system, was a useful prognostic indicator.
Angina scores incorporating the pattern of occurrence of
angina and the severity of symptoms unresponsive to medical
treatment or recurrent symptoms after revascularisation have
previously been shown to predict prognosis in the stable angina
population,17 18 but the predictive value lessens with longer
follow-up and is greatest in patients with preserved ventricular
function. The strength of angina symptoms in predicting
prognosis in this population may be related to the low
prevalence of pronounced ventricular dysfunction, the short
duration of follow-up, and the fact that most of these patients
were already on antianginal medications before presentation to a
cardiologist.
Risk prediction score
Several widely available multiple risk factors equations exist to
calculate the absolute risk of developing coronary or
cardiovascular disease in patients without established disease.3 4
However, such risk scores do not apply to a population with
symptoms. Although several scores have been developed to pre-
dict the presence of coronary disease by using clinical or exercise
variables or their combination,19 20 prognostic scores are
comparatively few and applicability is limited by restriction of the
population studied to those who can exercise.21 22 A modified
version of the Framingham risk equation exists, which has been
adapted for use in patients with pre-existing cardiovascular
disease,23 but this does not allow discrimination between initial
manifestations of coronary disease or presenting symptoms.
Cumulative data from single institution databases, such as the
Duke database, have also been used to synthesise nomograms to
assign absolute probabilities of coronary disease and mortality
given various combinations of data from clinical assessment,
non-invasive testing, and coronary angiography.23 However,
these tools were developed in populations assessed up to 30
years ago, are not specific to a stable angina population, and may
not be widely applicable.
The Euro heart angina score is simple and objective and
allows discrimination between an extremely low risk group
(annual rate of death and non-fatal infarction of < 0.5%) and
those at high risk over a one year period, in a population with a
clinical diagnosis of stable angina. The C-statistic for survival
derived from a physician’s initial assessment in the Duke
database was 0.82 when applied to a later cohort from Duke.24
Thus the predictive accuracy of this score is comparable to that
Table 7 Estimated probability of death or non-fatal myocardial infarction
over one year corresponding to selected values of the individual scores
Score* Estimated probability of death/myocardial infarction in 1 year (%)
0 0.57
10 0.63
20 0.70
30 0.77
40 0.85
50 0.94
60 1.04
70 1.14
80 1.26
90 1.40
100 1.54
110 1.70
120 1.88
130 2.08
140 2.29
150 2.53
160 2.79
170 3.08
180 3.39
190 3.75
200 4.13
210 4.56
220 5.03
230 5.54
240 6.11
250 6.73
260 7.41
270 8.15
280 8.97
290 9.86
300 10.84
310 11.91
320 13.08
330 14.35
340 15.74
350 17.24
360 18.87
370 20.64
380 22.54
390 24.60
400 26.80
410 29.16
420 31.69
430 34.37
440 37.21
450 40.21
460 43.36
470 46.65
*Log hazard ratios multiplied by 100.
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of older predictive models but is more relevant to a
contemporary population.
Conclusions
In patients presenting with stable angina, simple clinical features
are strongly predictive of prognosis. A low risk population may
be effectively identified by negative investigations, and those who
are not investigated constitute a high risk group. By identifying
the features most predictive of adverse outcome we have been
able to construct a simple scoring system to calculate an estimate
of the one year probability of death or non-fatal myocardial inf-
arction in patients with stable angina.
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What is already known on this topic
Contemporary data on clinical outcome in stable angina
outside randomised controlled trials are lacking, and in
recent clinical trials the annual mortality ranges from 0.9%
to 2.9%
Previous reports of the factors of prognostic importance in
stable coronary disease were drawn from highly selected
populations and predate modern drug management
What this study adds
In this contemporary evaluation of the prognosis associated
with stable angina, the incidence of death and myocardial
infarction was 2.3/100 patient years
Comorbidity, diabetes, severity of angina, shorter duration
of symptoms, left ventricular dysfunction, and ST changes
on the resting electrocardiogram independently predicted
outcome
A simple score involving these six characteristics can be
used to estimate the probability of death or myocardial
infarction in the year after presentation with stable angina
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